Anti-pembrolizumab antibodies
The present invention provides antibodies and antigen-binding fragments thereof that bind to the antibody pembrolizumab (pembrolizumab). These antibodies are useful, for example, for use as positive controls in assays for detecting the presence of anti-drug antibodies in a sample, e.g., the blood of a patient who has been administered pembrolizumab.
1. An antibody or antigen-binding fragment thereof that binds pembrolizumab, comprising: three light chain CDRs of CDR-L1, CDR-L2 and CDR-L3 and three heavy chain CDRs of CDR-H1, CDR-H2 and CDR-H3, wherein
CDR-L1 comprises the amino acid sequence: QASQSLSNLLA (SEQ ID NO: 25);
CDR-L2 comprises the amino acid sequence: GASNLES (SEQ ID NO: 26);
CDR-L3 comprises the amino acid sequence: QGGHYSGLT (SEQ ID NO: 27);
CDR-H1 comprises the amino acid sequence: TNDMN (SEQ ID NO: 28);
CDR-H2 comprises the amino acid sequence: VIYSDDTPDYATWAKG (SEQ ID NO: 29); and
CDR-H3 comprises the amino acid sequence: GHYDSAVYAYALNI (SEQ ID NO: 30).
2. The antibody or antigen-binding fragment of claim 1 which comprises a light chain immunoglobulin and a heavy chain immunoglobulin, wherein:
the light chain immunoglobulin comprises an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 11; and the heavy chain immunoglobulin comprises an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 12.
3. The antibody or antigen-binding fragment of claim 2 wherein said sequence identity is at least 95%.
4. The antibody or antigen-binding fragment of claim 1 comprising: a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 11; and a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 12.
5. The antibody of claim 1 , which is a monoclonal antibody.
6. A composition comprising an anti-pembrolizumab antibody or antigen-binding fragment thereof of claim 1 complexed with pembrolizumab.